We serve Chemical Name:[3-(3,5-dichlorophenyl)phenyl]methanol CAS:208941-51-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![[3-(3,5-dichlorophenyl)phenyl]methanol](https://a.dearchem.com/CAS2/208941-51-9.png)
Chemical Name:[3-(3,5-dichlorophenyl)phenyl]methanol
CAS.NO:208941-51-9
Synonyms:[3-(3,5-dichlorophenyl)phenyl]methanol
Molecular Formula:C13H10Cl2O
Molecular Weight:253.12400
HS Code:2906299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:393.9ºC at 760 mmHg
Density:1.315 g/cm3
Index of Refraction:
PSA:20.23000
Exact Mass:252.01100
LogP:4.15270
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like [3-(3,5-dichlorophenyl)phenyl]methanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[3-(3,5-dichlorophenyl)phenyl]methanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[3-(3,5-dichlorophenyl)phenyl]methanol Use and application,[3-(3,5-dichlorophenyl)phenyl]methanol technical grade,usp/ep/jp grade.
Related News: GEM Bstrong Family Necessities Kits we’re also donated https://www.globalempowermentmission.org/program/family-necessities-kits. Restaurant groups were organized to feed first responders and now we must ensure the survivors have stable and comfortable homes they can start all over in. methyl 2-(2-bromothiophen-3-yl)acetate manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 6-(3-chloro-5-ethoxyphenyl)-7-isopropyl-2-methylquinazolin-4(1H)-one suppliers In recent years, it has benefited significantly from the development of a broad range of enabling technologies, leading biocatalysis to become an established methodology for efficient, sustainable manufacturing, especially within the drug development industry. p-Toluolsulfonsaeure-((S)-2-methyl-2-hydroxypentyl)ester vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 6-(3-chloro-5-ethoxyphenyl)-7-isopropyl-2-methylquinazolin-4(1H)-one suppliers In recent years, it has benefited significantly from the development of a broad range of enabling technologies, leading biocatalysis to become an established methodology for efficient, sustainable manufacturing, especially within the drug development industry. p-Toluolsulfonsaeure-((S)-2-methyl-2-hydroxypentyl)ester vendor & factory.
